Opinion

Video

AUA 2024: Key Takeaways & Future of NMIBC Management

Author(s):

Gary Steinberg, MD, FACS

Gary D. Steinberg, MD, summarizes his major takeaway from the AUA 2024 conference and shares his insights on the potentially practice-changing developments he anticipates in the near future for the management of non-muscle-invasive bladder cancer (NMIBC).

Current Time 0:00
Duration 2:54
Loaded: 0.00%
Stream Type LIVE
Remaining Time 2:54
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following question:

    • What are takeaways from AUA 2024 that you would like to highlight?

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Anne Schuckman, MD, highlights promising new developments in NMIBC
    Anne Schuckman, MD, highlights promising new developments in NMIBC
    Vignesh Packiam, MD, on choosing between options in NMIBC
    Vignesh Packiam, MD, on choosing between options in NMIBC
    Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
    Strategies to bridge gender disparities in AAS and citations in the oncology literature
    1 expert in this video
    Selecting Between Receptor Pathway Inhibitors for mHSPC
    1 expert in this video
    The Use of Ultra-Low PSA in Specific Patient Profiles
    4 experts in this video
    Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
    1 expert in this video
    Using Ultrasensitive PSA Assays in Routine Practice
    1 expert in this video
    Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
    4 experts in this video
    Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
    Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
    Study findings highlight gender gaps in oncology authorship and citation
    Related Content
    FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC
    June 25th 2025

    FDA grants RMAT designation to detalimogene voraplasmid for high-risk NMIBC

    Hannah Clarke
    Detalimogene is currently under evaluation in the pivotal phase 1/2 LEGEND trial.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Human Urinary System Kidneys with Bladder Anatomy | Image Credit: © magicmine - stock.adobe.com
    June 13th 2025

    CHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBC

    Hannah Clarke
    The CHAI biomarker was shown to outperform EAU and AUA stratifications.
    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
    December 7th 2021

    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

    Urology Times staff
    “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
    Phase 2 trial of oncolytic immunotherapy launches in BCG-unresponsive NMIBC
    June 10th 2025

    Phase 2 trial of oncolytic immunotherapy launches in BCG-unresponsive NMIBC

    Hannah Clarke
    The objectives of the trial are to further confirm the recommended phase 2 dose and to assess the efficacy of MVR-T3011.
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    June 9th 2025

    En bloc resection of bladder tumor: Is it the way forward?

    Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
    "As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
    © 2025 MJH Life Sciences

    All rights reserved.